Malignant hyperthermia in dogs during general anaesthesia

Yıl 2017, Cilt: 1 Sayı: 3, 57 - 62, 25.09.2017

Özlem Güzel , Defne Şadalak Mckinstry

https://doi.org/10.30704/http-www-jivs-net.330592

Öz

Malignant
hyperthermia is a pharmacogenetic disorder of skeletal muscles developing as a
hypermetabolic response to inhalation anaesthetics such as halothane,
sevoflurane or isoflurane and depolarizing muscle relaxants such as
succinylcholine. It is produced by mutation of the RYR1 gene in dogs. In
anaesthetised dogs, regardless of the anaesthetic drugs used, calcium ion
channel activity may change and malignant hyperthermia may develop. Clinical features are hyperthermia,
tachypne, hypercarbia, increased oxygen consumption, severe metabolic acidosis,
hyperkalemia, cardiac arrhytmias and muscle rigidity. For a diagnosis of malignant
hyperthermia to be made, at least 3 of the clinical findings must be determined.
Dantrolene sodium is specific
antagonist of malignant
hyperthermia. However, it is not
usually preferred by veterinary practitioners due to its high cost as well as
the low incidence of the occurence of this complication. Therefore it is useful for
alternative drugs such as acepromazine,
diazepam and alfentanil to
be used for the treatment of clinical findings manifested during malignant
hyperthermia. The purpose of this review is to share with colleagues the
latest information regarding the treatment of canine malignant hyperthermia
occurring in relation to general anaesthesia. 

Anahtar Kelimeler

hyperthermia, anaesthesia, dog

Kaynakça

• Adami, C., Axiak, S., Raith, K., & Spadavecchia, C. (2012). Unusual perianesthetic malignant hyperthermia in a dog. Journal of the American Veterinary Medical Association, 240 (4), 450-453.
• Brunson, D. B., & Hogan, K. J. (2004). Malignant hyperthermia: a syndrome not a disease. The Veterinary Clinics of North America. Small Animal Practice, 34, 1419-1433.
• Chohan, A. S., & Greene, S. A. (2011). Anesthesia case of the month. Malignant hyperthermia. Journal of the American Veterinary Medical Association, 239 (7), 936-940.
• Fruen, B. R., Mickelson, J. R., & Louis, C. F. (1997). Dantrolene inhibition of sarcoplasmic reticulum Ca 2+ release by direct and specific action at skeletal muscle ryanodine receptors. The Journal of Biological Chemistry, 272 (24), 26965-26971.
• Gronert, G. A., & Milde, J. H. (1981). Variations in onset of porcine malignant hyperthermia. Anesthesia and Analgesia, 60 (7), 499-503.
• Guzel, O., Yildar, E., Karan, B., & Aydin, D. (2016, May 11-14). Malignant hyperthermia induced general anesthesia in an Anatolian Shepherd Dog. Paper presented at the 1st International Turkey Veterinary Surgery Congres. Erzurum, Turkey.
• Haskins, S. C. (2007). Monitoring anesthetized patients. In W.J. Tranquilli, J.C. Thurmon, K.A. Grimm (Ed). Lumb & Jones’ Veterinary Anesthesia and Analgesia. 4th ed. (pp. 533 - 558). Iowa, US : Blackwell Publishing.
• Karan, S. M., Lojeski, E. W., Haynes, D. H., Bina, S., Wesche, D. L., Boedeker, B. H., & Muldoon, S. M. (1996). Intravenous lecithin-coated microcrystals of dantrolene are effective in the treatment of malignant hyperthermia: An investigation in rats, dogs, and swine. Anesthesia and Analgesia, 82, 796-802.
• Kim, D.C. (2012). Malignant hyperthermia. Korean Journal of Anesthesiology, 63 (5), 391-401.
• Kirmayer, A. H., Klide, A. M., & Purvance, J. E. (1984). Malignant hyperthermia in a dog: Case report and review of the syndrome. Journal of the American Veterinary Medical Association, 185 (9), 978- 982.
• Krause, T., Gerbershagen, M., Fiege, M., Weiβhorn, R., & Wappler, F. (2004). Dantrolene – A review of its pharmacology, therapeutic use and new developments. Anaesthesia, 59, 364-373.
• Lamont, L. A., & Mathews, K. A. (2007): Opioids, nonsteroidal anti-inflammatories, and analgesic adjuvants. In W.J. Tranquilli, J.C. Thurmon, K.A. Grimm (Ed). Lumb & Jones’ Veterinary Anesthesia and Analgesia. 4th ed. (pp. 241-271). Iowa, US: Blackwell Publishing.
• Lemke, K. A. (2007). Anticholinergics and sedatives. In W.J. Tranquilli, J.C. Thurmon, K.A. Grimm (Ed). Lumb & Jones’ Veterinary Anesthesia and Analgesia. 4th ed. (pp. 203–239). Iowa, US: Blackwell Publishing.
• Lynch, C., Durbin, C. G., Fisher, N. A., Veselis, R. A., & Althaus, J. S. (1986). Effects of dantrolene and verapamil on atrioventricular conduction and cardiovascular performance in dogs. Anesthesia and Analgesia, 65, 252-258.
• Nelson, T. E. (1991). Malignant hyperthermia in dogs. Journal of the American Veterinary Medical Association, 198 (6), 989 - 994.
• O’Brien, P. J., Cribb, P. H., White, R. J., Olfert, E. D., & Steiss, J. E. (1983). Canine malignant hyperthermia: Diagnosis of susceptibility in a breeding colony. The Canadian Veterinary Journal, 24, 172-177.
• Otto, K. (1992). Malignant hyperthermia as a complication of anesthesia in the dog. Tierärztliche Praxis, 20 (5), 519-522.
• Roberts, M. C., Mickelson, J. R., Patterson, E. E., Nelson, T. E., Armstrong, P.J., Brunson, D.B., & Hogan, K. (2001). Autosomal dominant canine malignant hyperthermia is caused by a mutation in the gene encoding the skeletal muscle calcium release channel (RYR1). Anesthesiology, 95, 716-725.
• Rosenberg, H., Pollock, N., Schiemann, A., Bulger, T., & Stowell, K. (2015). Malignant hyperthermia: a review. Orphanet Journal of Rare Diseases, Doi 10,1186/s13023-015-0310-1.
• Saltzman, L. S., Kates, R. A., Corke, B. C., Norfleet, E. A., & Heath, K. R. (1984). Hyperkalemia and cardiovascular collapse after verapamil and dantrolene administration in swine. Anesthesia and Analgesia, 63, 473-478.
• Schneiderbanger, D., Johannsen, S., Rower, N., & Schuster, F. (2014). Management of malignant hyperthermia: Diagnosis and treatment. Therapeutics and Clinical Risk Management, 10, 355-362.
• Steffey, E. P., & Mama, K. R. (2007): Inhalation anesthetics. In W.J. Tranquilli, J.C. Thurmon, K.A. Grimm (Ed). Lumb & Jones’ Veterinary Anesthesia and Analgesia. 4th ed. (pp. 355 - 394). Iowa, US: Blackwell Publishing.